Tanezumab review finds pain benefits and a sensory side-effect signal
Results varied by outcome and dose in trials of chronic low back pain, with limited detail on benefit size and safety.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
The review found that the 10 mg tanezumab arm had greater reductions in back-pain scores than NSAIDs at the reported pain assessments. It also reported improvements in disability at selected assessments, alongside more abnormal peripheral sensations. Functional improvement with 5 mg did not differ significantly from NSAIDs; this does not establish superiority of either dose over the other.
The abstract gives no effect sizes, confidence intervals or detailed adverse-event counts. It does not provide enough information to resolve longer-term safety, including the joint-safety concerns mentioned by the authors.
What researchers found
Low back pain intensity scores
10 mg tanezumab versus NSAIDs at 1, 4, 8 and 12 weeks; statistically significant, with no effect sizes reported.
Function differed by assessment
Function was assessed with the Roland-Morris Disability Questionnaire. The reported functional advantage concerned selected follow-ups against NSAIDs. A nonsignificant result for the lower-dose arm leaves uncertainty about whether it differs from NSAIDs.
Reading the safety pattern
Overall adverse-event rates were described as similar to NSAIDs, but abnormal peripheral sensation was more frequent with the higher-dose arm. Similar overall rates do not show that every type of harm occurs equally often.
The original publication
Comparison of tanezumab and non-steroidal anti-inflammatory drugs in efficacy and safety for chronic low back pain: a systematic review and meta-analysis of randomized controlled trials.
Yao D, Li S, Pang L et al.
Front Neurol · 2025
- PubMed ID
- 40959499
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.